ViiV Healthcare is a global specialist HIV company dedicated to delivering advances in treatment and care for people living with HIV.
We are an independent pharmaceutical company established in 2009 by combining the power and expertise in the management of HIV from both GlaxoSmithKline (GSK) and Pfizer. Following a long-term collaboration on the joint development of several novel integrase inhibitors we were joined by Shionogi in 2012.
Our current portfolio of twelve HIV treatments generated annual sales of £1.5 billion in 2014 providing us with the financial stability to take a sustainable, long-term view when investing in our pipeline of new medicines. Our scientists are 100% dedicated to finding new ways to limit the impact of HIV on the 35 million people living with the virus and understanding how best to prevent and treat the disease. Find out more about our commitment to R&D.
Our dedicated staff of over 700 people are located in 15 countries and three regional hubs and we extend this geographical reach still further via our relationship with GSK. We are equipped to move quickly in response to the needs of the HIV community and have launched industry-leading access initiatives to help deliver on World Health Organisation (WHO)/UNAIDS goals to reach all those who need treatment. Find out more about our innovative and sustainable approach to access.
In addition, we actively support community initiatives in HIV, including the Positive Action programme, by partnering with like-minded organisations that share our ethos. Read more